Expert Opinion on Biological Therapy, Journal Year: 2025, Volume and Issue: unknown
Published: March 13, 2025
Introduction Ulcerative colitis (UC) is a chronic, relapsing and remitting, inflammatory bowel disease. Monoclonal antibodies targeting interleukin (IL)-23p19 have been developed to treat chronic diseases mediated by aberrant IL23/Th17 responses, including psoriasis, psoriatic arthritis, Crohn's More recently, these agents evaluated for the treatment of moderately-to-severely active UC.
Language: Английский